In Reply In our recently published study,1 we have shown an association of detection of circulating tumor DNA (ctDNA) in follow-up after treatment of breast cancer with a high risk of relapse. The results showed a substantial lead time over clinical relapse of 10.7 months overall and extending to 13.3 months in estrogen receptor–positive, ERBB2-negative breast cancer. This provides evidence for clinical validity of ctDNA molecular relapse assessment. However, our study does not provide evidence of clinical utility, which could only be generated from randomized clinical trials that assess whether treating patients on the basis of ctDNA assessment can improve outcome.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Garcia-Murillas I, Turner NC. Clinical Benefit of Circulating Tumor DNA Analysis in Follow-up of Patients With Early-Stage Breast Cancer—Reply. JAMA Oncol. 2020;6(3):439–440. doi:10.1001/jamaoncol.2019.5682
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: